Tag Archives: Wegovy

Weight-loss drug Wegovy offers benefits for people with diabetes and common form of heart failure, study finds – CNN

  1. Weight-loss drug Wegovy offers benefits for people with diabetes and common form of heart failure, study finds CNN
  2. Novo’s Wegovy Aids Heart Failure Patients With Diabetes in Study Bloomberg
  3. Wegovy’s heart benefits are not just linked with weight loss, new study suggests MarketWatch
  4. Study shows Wegovy easing heart failure symptoms for patients with diabetes—helpful to Novo Nordisk as it makes case insurers should pay for the weight-loss medication Fortune
  5. Positive trial results set up obesity drug Wegovy for use against heart failure STAT

Read original article here

Weight Loss Drug Wegovy Can Cut Heart Attack Risk for Some, Study Shows – The New York Times

  1. Weight Loss Drug Wegovy Can Cut Heart Attack Risk for Some, Study Shows The New York Times
  2. Novo Nordisk: Wegovy heart benefits due to more than weight loss Reuters
  3. Trial confirms heart benefits of Wegovy, but is weight loss responsible – or something else? CNN
  4. Obesity drug Wegovy cut risk of serious heart problems by 20%, study finds The Associated Press
  5. Novo Nordisk A/S: Semaglutide 2.4 mg (Wegovy®) cardiovascular outcomes data presented at American Heart Association Scientific Sessions and simultaneously published in New England Journal of Medicine Yahoo Finance
  6. View Full Coverage on Google News

Read original article here

Obesity drug Wegovy cut risk of serious heart problems by 20%, study finds – KSL.com

  1. Obesity drug Wegovy cut risk of serious heart problems by 20%, study finds KSL.com
  2. Novo Nordisk: Wegovy heart benefits due to more than weight loss Reuters
  3. Trial confirms heart benefits of Wegovy, but is weight loss responsible – or something else? CNN
  4. Weight Loss Drug Wegovy Can Cut Heart Attack Risk for Some, Study Shows The New York Times
  5. Novo Nordisk A/S: Semaglutide 2.4 mg (Wegovy®) cardiovascular outcomes data presented at American Heart Association Scientific Sessions and simultaneously published in New England Journal of Medicine Yahoo Finance
  6. View Full Coverage on Google News

Read original article here

Novo Nordisk snaps up Inversago Pharma for up to $1B+ on the back of megablockbuster Wegovy sales – Endpoints News

  1. Novo Nordisk snaps up Inversago Pharma for up to $1B+ on the back of megablockbuster Wegovy sales Endpoints News
  2. Novo Nordisk to acquire obesity drug developer Inversago Reuters
  3. Novo Nordisk bets $1.1B on Canadian biotech buyout, adding an old approach to obesity pipeline FierceBiotech
  4. Novo Nordisk to acquire Inversago Pharma to develop new therapies for people living with obesity, diabetes and other serious metabolic diseases GlobeNewswire
  5. Novo acquires Inversago for up to $1 billion, spotlighting troubled weight loss approach STAT
  6. View Full Coverage on Google News

Read original article here

Step aside Ozempic and Wegovy — ‘landmark’ trial results for weight-loss drug Mounjaro just dropped, and they – Business Insider India

  1. Step aside Ozempic and Wegovy — ‘landmark’ trial results for weight-loss drug Mounjaro just dropped, and they Business Insider India
  2. Lilly’s SURMOUNT-2 results published in The Lancet show tirzepatide achieved a mean weight reduction of 15.7% at the highest dose (15 mg) in adults with obesity or overweight and type 2 diabetes | Eli Lilly and Company Investors | Eli Lilly and Company
  3. ADA 2023 – Toxicity undermines Boehringer and Zealand’s incretin Evaluate Pharma
  4. Lilly’s phase 2 results published in the New England Journal of Medicine show orforglipron, a once-daily oral nonpeptide GLP-1 receptor agonist, achieved up to 14.7% mean weight reduction at 36 weeks in adults with obesity or overweight Yahoo Finance
  5. Lilly’s Mounjaro Gives Positive Results in Obese Diabetic People Bloomberg

Read original article here

Are fat-loss shots a ticking timebomb? Doctors warn Ozempic & Wegovy are shrinking patients’ muscles – Daily Mail

  1. Are fat-loss shots a ticking timebomb? Doctors warn Ozempic & Wegovy are shrinking patients’ muscles Daily Mail
  2. Weight loss drug semaglutide causes muscle loss, doctor warns Insider
  3. A doctor warns that weight-loss drug semaglutide is shrinking patients’ muscle mass at an alarming rate msnNOW
  4. Trendy weight-loss drug Ozempic is now a Hollywood punchline. See how doctors and clinics are using TikTok to Business Insider India
  5. A doctor warns that weight-loss drug semaglutide is shrinking patients’ muscle mass at an alarming rate Yahoo News
  6. View Full Coverage on Google News

Read original article here

Ozempic And Wegovy: What To Know About Semaglutide Weight Loss Drugs

A new class of weight loss drugs on the market have been making waves since they were authorized as a treatment for obesity in 2021. Semaglutide injections, which you may know as Wegovy or Ozempic, have become wildly popular over the past several months, thanks to the buzz they’ve received from TikTok influencers (and rumors of use among some celebrities).

The prescription injections were introduced as a diabetes treatment in 2017, but people soon realized that the medications — which help people with diabetes to manage their blood sugar levels — also led to significant weight loss in people with obesity who’d struggled to lose weight with other treatments.

From there, interest in the drugs grew, and after clinical trials confirmed what people suspected — that semaglutide injections help people lose weight — demand soared, so much so that pharmacies across the country are experiencing shortages in both Wegovy and Ozempic. Obesity specialists understand the hype; this kind of prescription weight loss medication has been a long time coming.

“For those of us who treat obesity, this is a game-changer we’ve never seen before,” said Dr. Dan Azagury, a bariatric surgeon at Stanford Health Care. “This is the first time ever that we have really effective drugs to treat obesity.”

Obesity is one of the most common chronic health conditions in the United States, but until recently, we haven’t had very effective drugs to address the health complications it’s commonly linked to, such as high cholesterol and high blood pressure. Aside from lifestyle changes like diet and exercise, the go-to intervention for obesity has been surgery (think: gastric bypass or the duodenal switch).

According to Azagury, many obesity specialists noticed that, in the wake of receiving bariatric surgery, many patients were suddenly no longer diabetic. Upon investigating the reason for this, researchers identified new gut hormones, including one called glucagon-like peptide (GLP-1), that reacted to food going into the gut.

Further testing revealed that GLP-1, which increases after bariatric surgery, improves blood sugar levels, and consequently helps with diabetes. “That’s why major diabetes goes away within days of surgery,” Azagury said.

After this discovery, pharmaceutical companies set out to form a diabetes drug that could activate those GLP-1 receptors. That’s what led to the development of semaglutidea synthetic compound that mimics the effects of GLP-1 ― and later the semaglutide-based diabetes drug Ozempic, which got approval from the Food and Drug Administration in 2017.

The other key finding about GLP-1: It slows down digestion and reduces food intake, according to Dr. Janelle Duah, a Yale Medicine internist. This is why Ozempic, which is intended for diabetes, has been and continues to be prescribed off-label for weight loss, Azagury said.

The weight loss effects of GLP-1 (which are revved up through semaglutide), combined with the wild demand for Ozempic, drove the drug manufacturer, Novo Nordisk, to create a very similar drug specifically for weight loss: Wegovy. Essentially just a stronger dosage of Ozempic, Wegovy got FDA approval in June 2021.

Who’s a candidate for the medications?

Wegovy, a once-a-week shot, is for adults who have a body mass index over 30, or who have a BMI above 27 with at least one weight-related health issue (think: high blood pressure, diabetes or high cholesterol). It’s also meant to supplement physical activity and dietary changes, which is why obesity specialists like Azagury recommend that patients work with a comprehensive team of providers, including dietitians and therapists, if they can afford to. Patients can get the prescription through their primary care doctor, too.

Many people find that the injections help them feel fuller longer and reduce sugary cravings. It “makes them crave protein and fiber more — thus helping them stick to diet changes that can further enhance their weight loss,” Duah said. Some people say it also reduced their desire to drink alcohol, and helped them to get better sleep.

Ozempic is approved for Type 2 diabetes, not obesity or weight loss, although people are getting it off-label for weight loss purposes. It’s entirely legal for doctors to prescribe meds off-label, but this is likely adding to ongoing drug shortages — which is a major issue for people with diabetes who can’t get hold of the medications.

Obesity doctors are excited that there’s finally a medication to help people, but there are some barriers and side effects to note.

What’s the overall take on these weight loss medications?

Obesity doctors are thrilled. Often, people retain weight because of health problems out of their control, not for lack of willpower or discipline. Many patients with obesity have tried it all, only to see minimal results. “Now we have something to help them,” Azagury said.

According to Duah, the recent surge in prescriptions, for the most part, is for good reason. “It is by far the most efficacious weight loss medication on the market, with users losing up to 20% of their starting body weight,” Duah said.

And even though interest in these drugs is soaring, Azagury thinks they can help still more people. The original class of obesity drugs from the 1960s and ’70s had nasty consequences and likely soured many people on the whole idea. It might take some convincing for more people to accept that there’s finally an effective drug for weight loss available, Azagury said.

There’s also the issue of cost. These drugs aren’t always covered by insurance, Azagury said, so it can get expensive (to the tune of $1,500 to $1,800 a month). “That is the biggest challenge people will face,” Azagury said. “It’s FDA-approved; that doesn’t mean insurance is going to pay for it.”

According to Duah, this is one of the main reasons providers end up prescribing Ozempic instead. Unlike Wegovy, Ozempic is often covered for diabetes or insulin resistance, so patients looking for semaglutide injections can get access to them at a reasonable price.

There are some risks associated with semaglutide injections

As with any drug, there are risks — but the injections are surprisingly well tolerated, Azagury said. The most common side effects are gastrointestinal issues, like nausea, vomiting, constipation, gas and heartburn. These GI-related side effects should subside as your body gets used to the injections; until then, they can mostly be handled by eating smaller, more frequent meals or taking over-the-counter medications like bismuth subsalicylate or heartburn relief tablets, Duah said. (If the side effects persist, be sure to talk to your doctor about finding relief or other, more tolerable options.)

In rare cases, semaglutide injections can lead to thyroid tumors, which can be cancerous. Other potential serious side effects include pancreatitis, gallbladder problems, low blood sugar, kidney issues, allergic reactions and depression. The injections also shouldn’t be used with other drugs that contain semaglutide or that target GLP-1 receptors.

We’re still learning about long-term side effects, since the drug is relatively new. The injections aren’t a quick fix, and most people will have to stay on the medications for at least a year (and likely longer) to meet their weight loss goals and improve their health, according to Azagury. One study found that many people who stop taking the medications rapidly gain the weight back, supporting the growing belief that the injections are meant to be taken for the long haul.

Other than a slightly higher risk of gallstones (which is common with many types of rapid weight loss), we haven’t seen any long-term effects with liraglutide, a similar drug that’s been on the market since 2010. Azagury expects the same will be true with semaglutide-based medications, given their similarity ― but, of course, time will tell.

If you’re interested in semaglutide injections, talk to your doctor. Understand the risks and benefits, and keep in mind that due to inflation, supply issues and growing demand, these drugs tend to be back-ordered — often for the people who need them most. Hopefully, supply will ramp up soon and more insurers will cover the cost. That, Duah said, will help more people get the drugs at a fair price.

“If insurances covered weight loss medications like Wegovy and supply was increased, we wouldn’t be seeing these issues with keeping Ozempic stocked on our pharmacies’ shelves,” Duah said.

fbq('init', '1621685564716533'); fbq('track', "PageView");

var _fbPartnerID = null; if (_fbPartnerID !== null) { fbq('init', _fbPartnerID + ''); fbq('track', "PageView"); }

(function () { 'use strict'; document.addEventListener('DOMContentLoaded', function () { document.body.addEventListener('click', function(event) { fbq('track', "Click"); }); }); })();

Read original article here

What it’s like to take the blockbuster drugs Ozempic and Wegovy, from severe side effects to losing 50 pounds

For the two months Carey Yazeed took Ozempic, the drug worked as intended. Yazeed has type 2 diabetes, and the weekly injection lowered her blood sugar levels. But it also brought side effects she considered unbearable, including vomiting, fatigue, headaches and stomach cramps.

Five weeks into taking the medication, Yazeed said, she found herself unable to move off the bathroom floor.

“I had vomited so much that I didn’t have the energy to get up and I was basically lying in it,” she said. “I couldn’t even raise my head to vomit in the commode. It was so bad.”

Dr. Carey Yazeed. (Courtesy Carey Yazeed.)

The severe effects Yazeed faced aren’t common, but people’s experiences taking Ozempic and its sister drug, Wegovy, can vary widely — from substantial weight loss and minimal discomfort on one end of the spectrum to extreme effects on the other.

NBC News spoke to 10 people about their experiences taking these blockbuster drugs, both of which are forms of semaglutide. They’re designed to mimic a hormone that signals to the brain when a person is full and promotes the release of insulin, a hormone that stops blood sugar from getting too high. In turn, the medications can lower blood sugar levels and suppress appetites.

They have soared in popularity over the last year, in part from social media attention and billionaires like Elon Musk touting the drugs’ weight loss effects.

Prescriptions for Ozempic tripled from 2021 to 2022, according to data from the prescription drug discount company SingleCare, which has more than 5 million members. Last year, high demand and global supply constraints gave rise to shortages of the medications. The FDA reported a Wegovy shortage in March 2022, followed by an Ozempic shortage in August.

Several people interviewed said the benefits they got from the drugs outweighed the side effects.

“It just feels lighter moving around. My clothes fit so much better and more comfortably,” said Stacey Bollinger, an account director in Maryland, who reported losing 52 pounds since starting Wegovy. “Something as simple as bending over to tie my shoe is so much easier.”

Stacey Bollinger. (Courtesy Stacey Bollinger)

Some people said they felt fine on the medications. But Yazeed and a couple of others described side effects that forced them to stop taking the drugs or question whether they could stay on them long term.

Obesity medicine experts who prescribe Ozempic and Wegovy said the drugs can transform patients’ lives and health. The weight loss effects can enable patients to do activities they couldn’t do previously, like chase after grandchildren or find clothes that fit at mainstream stores. Semaglutide can also address health issues linked to obesity and diabetes, such as an elevated risk of heart attacks or stroke.

“By treating obesity, you’re effectively potentially treating over 200 other obesity-related or weight-related diseases,” said Dr. Ania Jastreboff, an associate professor of medicine at the Yale School of Medicine. Jastreboff serves on the scientific advisory board of Novo Nordisk, which makes Ozempic and Wegovy.

Accounts of dramatic weight loss

The Food and Drug Administration approved Ozempic for people with type 2 diabetes in 2017, then Wegovy — the same drug, which goes up to higher dosage — in 2021 for weight loss in adults with obesity or those who are overweight and have least one weight-related health condition, such as high blood pressure or cholesterol. Ozempic is not approved for weight loss, but doctors sometimes prescribe it off-label for that purpose.

Most people who took Ozempic or Wegovy said it curbed their hunger and reduced cravings for unhealthy food. Bollinger and Randi Lee Harper, a software developer in the Seattle area, each reported losing more than 50 pounds.

Harper took Ozempic off-label for weight loss from May until November (she paused while moving to Washington state but plans to start again). She said she still enjoyed her favorite foods — like truffle mac n’ cheese and Sour Patch Kids candy — but her portions were smaller.

“You don’t realize how much your life is centered around food when you’re overweight until you’re on a diet that just lets you not think about it so much, like on Ozempic,” Harper said.

For the most part, she added, she reacted well to the medication, though sometimes she burped if she ate too much — a fairly common side effect.

As for Bollinger, she said that in addition to her weight loss, her average blood sugar levels have dropped to a point where she’s no longer pre-diabetic.

A study of more than 1,000 people with type 2 diabetes found that semaglutide was more effective than insulin at lowering blood sugar. The participants had not seen results from other antidiabetic drugs, which they continued to take during the trial. In another study of nearly 2,000 overweight or obese adults without diabetes, people taking semaglutide lost an average of 34 pounds in less than 16 weeks, compared to 6 pounds among those receiving a placebo.

Dr. C. Nicole Swiner, a family medicine doctor in Durham, North Carolina, said she started taking Wegovy in 2021 after seeing how much it helped her patients. She has lost 30 pounds since then, she said.

“Because I’m not starving, I can actually stop and make a smarter decision [rather] than, ‘Oh my God, I’m ravenous. Let me grab whatever’s in the office kitchen,’ which is usually junk,” Swiner said.

C. Nicole Swiner. (Chris Charles)

On Wegovy, she added, she eats less overall and has swapped sugary treats like cookies or muffins for healthier alternatives like yogurt or fruit.

For Yazeed, weight loss was not the reason she went on Ozempic, nor was it a goal. But on the drug, she said, she had to force herself to eat and often couldn’t stomach anything beyond a protein shake in the morning. On a good day, she might also tolerate some chicken broth.

She lost 10 pounds in two months, going from a size 12 to an 8 or 10.

Patients who stop taking the drugs often regain weight

Like many drugs, the effects of semaglutide stop when patients go off of it, so some people regain weight. Experts said they consider Ozempic and Wegovy to be lifelong medications.

“Data from our clinical trials for Wegovy showed that, not unexpectedly, patients experience weight regain once they stop taking the medication,” Novo Nordisk told NBC News in a statement.

“This supports the belief that obesity is a chronic disease that requires long-term management, much like high blood pressure or high cholesterol, for which most patients remain on therapy long term,” the company added.

Ebony Wiggins, who has type 2 diabetes, said she has gained back about 15 pounds of the 25 she lost last year while taking Ozempic.

Artemis Bayandor, who lives in Naperville, Illinois, said she weighs more now than when she took Wegovy: Within one month of stopping the medication, she gained back the 15 pounds she had lost on the drug, she said, plus an extra 10 over the next six months.

“For the first week I was OK, and for the second week I went right back to all of the cravings, but worse,” Bayandor said.

Side effects put some people off the medications

Courtney Hamilton didn’t made it more than a month on Ozempic, which her doctor prescribed off-label because Hamilton has type 1 diabetes, not type 2.

Her nausea got so bad that she could barely eat, Hamilton said, and the foods she could tolerate weren’t particularly healthy.

“Ironically, it made me stick to very starchy, carby foods like potatoes because they’re very bland. I ate a lot of that and a lot of plain toast,” she said.

People typically start with a low dose of Ozempic or Wegovy, then ramp up to reduce side effects. Dr. Fatima Cody Stanford, an assistant professor of medicine at Massachusetts General Hospital, said some severe effects may be the result of raising that dosage too quickly.

“If the patient’s saying, ‘Oh gosh, I’m sick. I can’t even go to work, I’m vomiting all day,’ it’s probably the dose is just not an appropriate dose for them,” Stanford said.

In clinical trials, 73% of adults taking the highest dose of Wegovy reported gastrointestinal issues. Nausea, diarrhea, vomiting, constipation and stomach pain are most common. Some people have reported more serious, albeit rare, side effects like pancreatitis and kidney failure.

Novo Nordisk said patients experiencing nausea as a side effect should contact their health care provider for guidance about ways to manage it.

Jastreboff said she encourages her patients to consume smaller, more frequent meals, not eat past the point of fullness, and monitor which foods exacerbate their symptoms. Most side effects occur as people are increasing their dosage, then subside once they reach the maintenance phase, she added.

Megan Cornelius, who has been taking Ozempic off-label for type 1 diabetes for several years, said she was nauseous and fatigued at first but those effects faded over time.

“As long as I can continue to take it, I probably will,” Cornelius said.

Eric Joiner Jr. (Cortesía de Eric Joiner Jr.)

For Eric Joiner Jr., a former type 2 diabetic, Ozempic hasn’t done anything beyond its intended effect: improve his kidney function — an off-label application of the drug. Joiner developed chronic kidney disease as a byproduct of his diabetes.

He hasn’t experienced side effects or weight loss from Ozempic, he said, but he recognizes that isn’t true for everyone.

“At the end of the day, it’s a very personal thing,” he said. “Your biology is different than mine.”

This story originally appeared on NBCNews.com.

This article was originally published on TODAY.com

Read original article here

Type 2 diabetes drug Ozampic is facing shortage after approved by FDA as weight loss drug Wegovy

Monday, January 16, 2023 1:57AM

Demand for a diabetes drug is on the rise, but the reason for that demand is being called into question.

The drug semaglutide was initially marketed under the name Ozempic to manage type 2 diabetes, but last year, it was approved by the FDA to be used for weight loss under the name Wegovy.

But now, the drug manufacturer Novo Nordisk is struggling to meet demand, which doctors say is creating a problem for type 2 diabetes patients.

RELATED: National Diabetes Awareness Month: Knowing signs and symptoms

“Our patients with diabetes are struggling just to get their medications to control their blood sugars and so we’re having to substitute other medications, increase their insulin requirements. People are gaining weight back from not being on these medications and so it really is becoming a problem for our patients that are dealing with type 2 diabetes. But then again, there is an epidemic of obesity, as well and we need to treat the obesity to prevent the diabetes in the first place,” said Dr. Disha Narang.

According to the CDC, more than 37 million Americans have diabetes 90% to 95% of them have type 2 diabetes.

Read original article here

Experts Recommend Drugs, Surgery for Teen Obesity in New Guidelines

Image: Shutterstock (Shutterstock)

For the first time ever, experts with the American Academy of Pediatrics are recommending proactive medical intervention against childhood obesity. The organization’s new guidelines will no longer ask doctors to simply observe or delay treatment in children with obesity, defined as a body mass index over 30. They instead now emphasize a range of options, such as dietary and lifestyle counseling for younger children as well as medications and/or surgery for children 12 and over.

Past standards for treating childhood obesity have called for “watchful waiting,” the hope being that a child’s BMI (a measure of both weight and height) would naturally lower over time as they grew. In 2007, the AAP’s previous recommendations promoted a step-based approach, where doctors might slowly escalate from observation to treatment. But these new recommendations—released Monday—are the first clinical practice guidelines to put obesity treatments front and center.

“There is no evidence that ‘watchful waiting’ or delayed treatment is appropriate for children with obesity,” said Sandra Hassink, one of the authors behind the guidelines and vice chair of the AAP Clinical Practice Guideline Subcommittee on Obesity, in a statement released by the organization. “The goal is to help patients make changes in lifestyle, behaviors or environment in a way that is sustainable and involves families in decision-making at every step of the way.”

The lengthy guidelines outline a multitude of available treatments, depending on a child’s age and other circumstances (children under 2 are not considered eligible for obesity treatment).

For younger children, these options can include intensive health behavior and lifestyle treatment, which can involve regular counseling sessions with the child and family over a 3- to 12-month period. For children 12 and over, doctors are now advised to consider medications as a front-line option. And teens 13 and over can also be evaluated for bariatric surgery as a potential treatment.

In crafting its recommendations, the AAP cites many studies suggesting that the benefits of these treatments outweigh any potential risks they can carry. Patients who have undergone bariatric surgery seem to have a lower risk of developing obesity-related complications such as type 2 diabetes and have a longer life expectancy when compared to non-surgical patients matched in age and baseline BMI, for instance. Long-term health benefits have been seen in teen bariatric patients specifically, too.

A new class of medication, called incretins, has also greatly changed the landscape of obesity treatment in recent years. These drugs, combined with diet and exercise, have led to far larger weight loss on average than most other treatments and are approaching the typical results seen with bariatric surgery.

Last month, the Food and Drug Administration extended the approval of Novo Nordisk’s Wegovy, the first drug of this new generation, to children over 12, following clinical trial data showing that teens saw a similar improvement in BMI as adults. The shortages that have plagued Wegovy’s rollout since its approval in June 2021 may finally be over as well, with the company recently announcing that its supply should now be stable. Without insurance coverage, which is often limited, the drug can still cost over $1,000 a month, however.

The AAP’s guidelines arrive at a time when the rise in U.S. obesity rates, including among children, has only accelerated, likely in part due to the covid-19 pandemic. The new recommendations notably do not cover how best to prevent obesity in children, though the organization has promised to release separate recommendations for that in the near future.

“The medical costs of obesity on children, families and our society as a whole are well-documented and require urgent action,” said lead author Sarah Hampl in a statement. “This is a complex issue, but there are multiple ways we can take steps to intervene now and help children and teens build the foundation for a long, healthy life.”

Read original article here